Article
Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34+ cell…
medRxiv · 2024 · Katta, V.; O'Keefe, K.; Li, Y.; Mayuranathan, T.; Levine, R. M.; Lazzarotto, C. R.; Wood, R. K.; Powers, A.; Mayberry, K.; Manquen, G.; Yao, Y.; Zhang, J.; Jang, Y.; Nimmagadda, N.; Dempsey, E. A.; Lee, G.; Uchida, N.; Cheng, Y.; Fazio, F.; Lockey, T.; Meagher, M.; Sharma, A.; Tisdale, J. F.; Zhou, S.; Yen, J. S.; Weiss, M. J.; Tsai, S. Q.
Key facts
| Title | Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34+ cell therapy to induce fetal hemoglobin for sickle cell disease |
|---|---|
| First author | Katta, V.; O'Keefe, K.; Li, Y.; Mayuranathan, T.; Levine, R. M.; Lazzarotto, C. R.; Wood, R. K.; Powers, A.; Mayberry, K.; Manquen, G.; Yao, Y.; Zhang, J.; Jang, Y.; Nimmagadda, N.; Dempsey, E. A.; Lee, G.; Uchida, N.; Cheng, Y.; Fazio, F.; Lockey, T.; Meagher, M.; Sharma, A.; Tisdale, J. F.; Zhou, S.; Yen, J. S.; Weiss, M. J.; Tsai, S. Q. |
| Journal | medRxiv |
| Published | Jan 1, 2024 |
| DOI | 10.1101/2024.04.30.591737 |
| Devices mentioned | K013988, K023892, K042152, K152294, K190495, K233719, K790445, K914390, K934069, K940422, K963717, K982100 |
| Product codes mentioned | BSN, CFN, DDG, DFZ, FIB, JRL, KPR, IZL, MQB, MVU, OVG, PFF and 1 more |
At a glance
- 10–99 FDA submissions mentioned
- 10–99 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1